Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea Reginald V. Fant, Jack E. Henningfield, Brooks D. Cash, Leonard S. Dove, Paul S. Covington Clinical Gastroenterology and Hepatology Volume 15, Issue 7, Pages 1021-1029.e6 (July 2017) DOI: 10.1016/j.cgh.2017.01.026 Copyright © 2017 AGA Institute Terms and Conditions
Figure 1 SOWS scores 0, 1, 2, 3, and >3 days after treatment discontinuation. Clinical Gastroenterology and Hepatology 2017 15, 1021-1029.e6DOI: (10.1016/j.cgh.2017.01.026) Copyright © 2017 AGA Institute Terms and Conditions